Cargando…

Subtractive proteomics analysis to uncover the potent drug targets for distinctive drug design of Candidaauris

Candida auris is a serious health concern of the current world that possesses a serious global health threat and is emerging at a high rate. Available antifungal drugs are failing to combat this pathogen as they are growing resistant to those drugs and some strains have already shown resistance to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bappy, Md. Nazmul Islam, Robin, Tanjin Barketullah, Prome, Anindita Ash, Patil, Rajesh B., Moin, Abu Tayab, Akter, Rupali, Laskar, Fayeza Sadia, Roy, Anindita, Akter, Hafsa, Zinnah, Kazi Md. Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361121/
https://www.ncbi.nlm.nih.gov/pubmed/37484251
http://dx.doi.org/10.1016/j.heliyon.2023.e17026
_version_ 1785076163530457088
author Bappy, Md. Nazmul Islam
Robin, Tanjin Barketullah
Prome, Anindita Ash
Patil, Rajesh B.
Moin, Abu Tayab
Akter, Rupali
Laskar, Fayeza Sadia
Roy, Anindita
Akter, Hafsa
Zinnah, Kazi Md. Ali
author_facet Bappy, Md. Nazmul Islam
Robin, Tanjin Barketullah
Prome, Anindita Ash
Patil, Rajesh B.
Moin, Abu Tayab
Akter, Rupali
Laskar, Fayeza Sadia
Roy, Anindita
Akter, Hafsa
Zinnah, Kazi Md. Ali
author_sort Bappy, Md. Nazmul Islam
collection PubMed
description Candida auris is a serious health concern of the current world that possesses a serious global health threat and is emerging at a high rate. Available antifungal drugs are failing to combat this pathogen as they are growing resistant to those drugs and some strains have already shown resistance to all three available antifungal drugs in the market. Hence, finding alternative therapies is essential for saving lives from this enemy. To make the development of new treatments easier, we conducted some in silico study of this pathogen to discover possible targets for drug design and also recommended some possible metabolites to test in vivo circumstances. The complete proteome of the representative strain was retrieved, and the duplicate, non-essential, human homologous, non-metabolic, and druggable proteins were then eliminated. As a result, out of a total of 5441 C. auris proteins, we were able to isolate three proteins (XP 028890156.1, XP 028891672.1, and XP 028891858.1) that are crucial for the pathogen's survival as well as host-non-homolog, metabolic, and unrelated proteins to the human microbiome. Their subcellular locations and interactions with a large number of proteins (10 proteins) further point to them being good candidates for therapeutic targets. Following in silico docking of 29 putative antifungals of plant origin against the three proteins we chose, Caledonixanthone E, Viniferin, Glaucine, and Jatrorrhizine were discovered to be the most effective means of inhibiting those proteins since they displayed higher binding affinities (ranging from −28.97 kcal/mol to −51.99 kcal/mol) than the control fluconazole (which ranged between −28.84 kcal/mol and −41.15 kcal/mol). According to the results of MD simulations and MM-PBSA calculations, Viniferin and Caledonixanthone E are the most effective ligands for the proteins XP 028890156.1, XP 028891672.1, and XP 028891858.1. Furthermore, they were predicted to be safe and also showed proper ADME properties.
format Online
Article
Text
id pubmed-10361121
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103611212023-07-22 Subtractive proteomics analysis to uncover the potent drug targets for distinctive drug design of Candidaauris Bappy, Md. Nazmul Islam Robin, Tanjin Barketullah Prome, Anindita Ash Patil, Rajesh B. Moin, Abu Tayab Akter, Rupali Laskar, Fayeza Sadia Roy, Anindita Akter, Hafsa Zinnah, Kazi Md. Ali Heliyon Research Article Candida auris is a serious health concern of the current world that possesses a serious global health threat and is emerging at a high rate. Available antifungal drugs are failing to combat this pathogen as they are growing resistant to those drugs and some strains have already shown resistance to all three available antifungal drugs in the market. Hence, finding alternative therapies is essential for saving lives from this enemy. To make the development of new treatments easier, we conducted some in silico study of this pathogen to discover possible targets for drug design and also recommended some possible metabolites to test in vivo circumstances. The complete proteome of the representative strain was retrieved, and the duplicate, non-essential, human homologous, non-metabolic, and druggable proteins were then eliminated. As a result, out of a total of 5441 C. auris proteins, we were able to isolate three proteins (XP 028890156.1, XP 028891672.1, and XP 028891858.1) that are crucial for the pathogen's survival as well as host-non-homolog, metabolic, and unrelated proteins to the human microbiome. Their subcellular locations and interactions with a large number of proteins (10 proteins) further point to them being good candidates for therapeutic targets. Following in silico docking of 29 putative antifungals of plant origin against the three proteins we chose, Caledonixanthone E, Viniferin, Glaucine, and Jatrorrhizine were discovered to be the most effective means of inhibiting those proteins since they displayed higher binding affinities (ranging from −28.97 kcal/mol to −51.99 kcal/mol) than the control fluconazole (which ranged between −28.84 kcal/mol and −41.15 kcal/mol). According to the results of MD simulations and MM-PBSA calculations, Viniferin and Caledonixanthone E are the most effective ligands for the proteins XP 028890156.1, XP 028891672.1, and XP 028891858.1. Furthermore, they were predicted to be safe and also showed proper ADME properties. Elsevier 2023-06-06 /pmc/articles/PMC10361121/ /pubmed/37484251 http://dx.doi.org/10.1016/j.heliyon.2023.e17026 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Bappy, Md. Nazmul Islam
Robin, Tanjin Barketullah
Prome, Anindita Ash
Patil, Rajesh B.
Moin, Abu Tayab
Akter, Rupali
Laskar, Fayeza Sadia
Roy, Anindita
Akter, Hafsa
Zinnah, Kazi Md. Ali
Subtractive proteomics analysis to uncover the potent drug targets for distinctive drug design of Candidaauris
title Subtractive proteomics analysis to uncover the potent drug targets for distinctive drug design of Candidaauris
title_full Subtractive proteomics analysis to uncover the potent drug targets for distinctive drug design of Candidaauris
title_fullStr Subtractive proteomics analysis to uncover the potent drug targets for distinctive drug design of Candidaauris
title_full_unstemmed Subtractive proteomics analysis to uncover the potent drug targets for distinctive drug design of Candidaauris
title_short Subtractive proteomics analysis to uncover the potent drug targets for distinctive drug design of Candidaauris
title_sort subtractive proteomics analysis to uncover the potent drug targets for distinctive drug design of candidaauris
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361121/
https://www.ncbi.nlm.nih.gov/pubmed/37484251
http://dx.doi.org/10.1016/j.heliyon.2023.e17026
work_keys_str_mv AT bappymdnazmulislam subtractiveproteomicsanalysistouncoverthepotentdrugtargetsfordistinctivedrugdesignofcandidaauris
AT robintanjinbarketullah subtractiveproteomicsanalysistouncoverthepotentdrugtargetsfordistinctivedrugdesignofcandidaauris
AT promeaninditaash subtractiveproteomicsanalysistouncoverthepotentdrugtargetsfordistinctivedrugdesignofcandidaauris
AT patilrajeshb subtractiveproteomicsanalysistouncoverthepotentdrugtargetsfordistinctivedrugdesignofcandidaauris
AT moinabutayab subtractiveproteomicsanalysistouncoverthepotentdrugtargetsfordistinctivedrugdesignofcandidaauris
AT akterrupali subtractiveproteomicsanalysistouncoverthepotentdrugtargetsfordistinctivedrugdesignofcandidaauris
AT laskarfayezasadia subtractiveproteomicsanalysistouncoverthepotentdrugtargetsfordistinctivedrugdesignofcandidaauris
AT royanindita subtractiveproteomicsanalysistouncoverthepotentdrugtargetsfordistinctivedrugdesignofcandidaauris
AT akterhafsa subtractiveproteomicsanalysistouncoverthepotentdrugtargetsfordistinctivedrugdesignofcandidaauris
AT zinnahkazimdali subtractiveproteomicsanalysistouncoverthepotentdrugtargetsfordistinctivedrugdesignofcandidaauris